Summit Therapeutics Inc (SMMT) has a current Price-to-Book (P/B) ratio of 67.84. Compared to its 3-year average P/B ratio of 42.44, the current P/B ratio is approximately 59.84% higher. Relative to its 5-year average P/B ratio of 26.43, the current P/B ratio is about 156.69% higher. Summit Therapeutics Inc (SMMT) has a Forward Free Cash Flow (FCF) yield of approximately -2.00%. Compared to its 3-year average FCF yield of -2.12%, the current FCF yield is approximately -5.76% lower. Relative to its 5-year average FCF yield of -11.77%, the current FCF yield is about -83.01% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SMMT competitors is 40.47, providing a benchmark for relative valuation. Summit Therapeutics Inc Corp (SMMT.O) exhibits a P/S ratio of 171.83, which is 324.62% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SMMT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SMMT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SMMT currently overvalued or undervalued?

What is Summit Therapeutics Inc (SMMT) fair value?

SMMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Summit Therapeutics Inc (SMMT) is between to according to relative valuation method.

How does SMMT's valuation metrics compare to the industry average?

The average P/S ratio for SMMT's competitors is 40.47, providing a benchmark for relative valuation. Summit Therapeutics Inc Corp (SMMT) exhibits a P/S ratio of 171.83, which is 324.62% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Summit Therapeutics Inc (SMMT) as of Mar 03 2026?

As of Mar 03 2026, Summit Therapeutics Inc (SMMT) has a P/B ratio of 67.84. This indicates that the market values SMMT at 67.84 times its book value.

What is the current FCF Yield for Summit Therapeutics Inc (SMMT) as of Mar 03 2026?

As of Mar 03 2026, Summit Therapeutics Inc (SMMT) has a FCF Yield of -2.00%. This means that for every dollar of Summit Therapeutics Inc's market capitalization, the company generates -2.00 cents in free cash flow.

What is the current Forward P/E ratio for Summit Therapeutics Inc (SMMT) as of Mar 03 2026?

As of Mar 03 2026, Summit Therapeutics Inc (SMMT) has a Forward P/E ratio of -51.56. This means the market is willing to pay $-51.56 for every dollar of Summit Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Summit Therapeutics Inc (SMMT) as of Mar 03 2026?

As of Mar 03 2026, Summit Therapeutics Inc (SMMT) has a Forward P/S ratio of 171.83. This means the market is valuing SMMT at $171.83 for every dollar of expected revenue over the next 12 months.

SMMT Valuation